Cargando…

Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model

3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouazza, Asma, Favier, Roland, Fontaine, Eric, Leverve, Xavier, Koceir, Elhadj-Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329750/
https://www.ncbi.nlm.nih.gov/pubmed/35893898
http://dx.doi.org/10.3390/nu14153044
_version_ 1784757990635601920
author Bouazza, Asma
Favier, Roland
Fontaine, Eric
Leverve, Xavier
Koceir, Elhadj-Ahmed
author_facet Bouazza, Asma
Favier, Roland
Fontaine, Eric
Leverve, Xavier
Koceir, Elhadj-Ahmed
author_sort Bouazza, Asma
collection PubMed
description 3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet (ND-controlled) or a HED (High-Energy Diet) divided in: HED- controlled, HED-3,5-T2 and HED- Placebo groups. 3,5-T2 has been tested at 25 µg dose and was administered under subcutaneous pellet implant during 10 weeks. Isolated hepatocytes were shortly incubated with 3,5-T2 at 10(−6) M and 10(−9) M dose in the presence energetic substrates. 3,5-T2 treatment reduce visceral adipose tissue, prevent the insulin resistance, attenuated hyperglycemia, dyslipidemia, and reversed liver steatosis in diabetes P. obesus. 3,5-T2 decreased gluconeogenesis, increased ketogenesis and enhanced respiration capacity. 3,5-T2 potentiates redox and phosphate potential both in cytosol and mitochondrial compartment. The use of 3,5-T2 as a natural therapeutic means to regulate cellular energy metabolism. We suggest that 3,5-T2 may help improve the deleterious course of obesity and T2DM, but cannot replace medical treatment.
format Online
Article
Text
id pubmed-9329750
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93297502022-07-29 Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model Bouazza, Asma Favier, Roland Fontaine, Eric Leverve, Xavier Koceir, Elhadj-Ahmed Nutrients Article 3,5-Diiodothyronine (3,5-T2) has been shown to exert pleiotropic beneficial effects. In this study we investigated whether 3,5-T2 prevent several energy metabolism disorders related to type 2 diabetes mellitus (T2DM) in gerbils diabetes-prone P. obesus. 157 male gerbils were randomly to Natural Diet (ND-controlled) or a HED (High-Energy Diet) divided in: HED- controlled, HED-3,5-T2 and HED- Placebo groups. 3,5-T2 has been tested at 25 µg dose and was administered under subcutaneous pellet implant during 10 weeks. Isolated hepatocytes were shortly incubated with 3,5-T2 at 10(−6) M and 10(−9) M dose in the presence energetic substrates. 3,5-T2 treatment reduce visceral adipose tissue, prevent the insulin resistance, attenuated hyperglycemia, dyslipidemia, and reversed liver steatosis in diabetes P. obesus. 3,5-T2 decreased gluconeogenesis, increased ketogenesis and enhanced respiration capacity. 3,5-T2 potentiates redox and phosphate potential both in cytosol and mitochondrial compartment. The use of 3,5-T2 as a natural therapeutic means to regulate cellular energy metabolism. We suggest that 3,5-T2 may help improve the deleterious course of obesity and T2DM, but cannot replace medical treatment. MDPI 2022-07-25 /pmc/articles/PMC9329750/ /pubmed/35893898 http://dx.doi.org/10.3390/nu14153044 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bouazza, Asma
Favier, Roland
Fontaine, Eric
Leverve, Xavier
Koceir, Elhadj-Ahmed
Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
title Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
title_full Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
title_fullStr Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
title_full_unstemmed Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
title_short Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model
title_sort potential applications of thyroid hormone derivatives in obesity and type 2 diabetes: focus on 3,5-diiodothyronine (3,5-t2) in psammomys obesus (fat sand rat) model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329750/
https://www.ncbi.nlm.nih.gov/pubmed/35893898
http://dx.doi.org/10.3390/nu14153044
work_keys_str_mv AT bouazzaasma potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel
AT favierroland potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel
AT fontaineeric potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel
AT levervexavier potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel
AT koceirelhadjahmed potentialapplicationsofthyroidhormonederivativesinobesityandtype2diabetesfocuson35diiodothyronine35t2inpsammomysobesusfatsandratmodel